Skip to content

Comparison of Two Different Medications Used to Treat Elevated Intracranial Pressure

Prospective, Randomized Clinical Trialto Compare Mannitol and Hypertonic Saline for Treatment of Increased Intracranial Pressure

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00359697
Enrollment
50
Registered
2006-08-02
Start date
Unknown
Completion date
Unknown
Last updated
2014-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Increased Intracranial Pressure

Brief summary

The overall purpose of this study is to compare the effects of mannitol and hypertonic saline on patients with increased intracranial pressure. The hypothesis being tested is that hypertonic saline is more effective in controlling increased intracranial pressure than mannitol.

Interventions

DRUGHypertonic Saline, Mannitol

Sponsors

Thomas Jefferson University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Documented SAH (by computed tomography or lumbar puncture), ICH, TBI or brain tumor * Patient greater than or equal to 18 years of age * ICP monitor in place * ICP greater than 20mmHg, not related to a transient noxious stimulus and not responding to standard measures for controlling ICP (ventricular drainage, elevation of head of the bed and optimizing PaCO2) * Patient or patient's legally authorized representative has provided written informed consent

Exclusion criteria

* Patient less than 18 years of age * Lack of ICP monitoring * Patient received Mannitol prior to placement of ICP monitor * Baseline serum osmolarity of greater than 310 mOsm/L * Patient is currently enrolled in another investigational drug or device study * Congestive heart failure at time of enrollment * Chronic renal failure on hemodialysis * Pregnancy

Design outcomes

Primary

MeasureTime frame
Reduction of ICP below treatment threshold (less than 20 mmHg)

Secondary

MeasureTime frame
Compare effects of each treatment on MAP, CPP, serum and urine sodium and osmolality

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026